Genfit Rises 4% On Tripled Iqirvo Royalty Rate, Runway Now Past 2028

Genfit shares gained 4% on the latest session after the French biotech reported that royalties from Iqirvo, its treatment for a chronic liver disease, have tripled. The company said the increased royalty income extends its cash runway beyond 2028, removing near-term pressure to raise additional financing. The royalty jump matters because Genfit, like many smaller biotechs, has historically depended on partner payments and milestone royalties to fund operations rather than product sales of its own. A tripling of that royalty stream gives the company more room to invest in its pipeline without diluting shareholders through a capital raise. What is not yet clear from Wednesday's update is what specifically drove the tripling — whether it reflects higher Iqirvo sales volumes by its commercial partner, a renegotiated royalty rate, or both. That detail would matter for judging whether the higher royalty run rate is sustainable into 2027 and beyond.